Search

Your search keyword '"Pin, Isabelle"' showing total 9 results
9 results on '"Pin, Isabelle"'

1. HOMA indices as screening tests for cystic fibrosis-related diabetes.

Author

Toin T, Reynaud Q, Denis A, Durieu I, Mainguy C, Llerena C, Pin I, Touzet S, and Reix P

Subjects
Adolescent, Adult, Biomarkers blood, Child, Cohort Studies, Female, Humans, Insulin Resistance, Male, Predictive Value of Tests, Prospective Studies, Young Adult, Blood Glucose metabolism, Cystic Fibrosis complications, Diabetes Mellitus diagnosis, Glucose Tolerance Test, Insulin blood, Insulin-Secreting Cells metabolism
Abstract

Background: We assessed the diagnostic performances of homeostasis model assessment indices (HOMA) of β-cell function (HOMA-%β) and of insulin resistance (HOMA-IR) for cystic fibrosis related diabetes (CFRD) screening., Methods: Data were collected from a prospective cohort of 228 patients with CF (117 adults and 111 children). Fasting insulin and glucose levels were measured to calculate HOMA-%β and HOMA-IR. HOMA-%β <100 indicated insulin secretion deficiency and HOMA-IR >1 insulin resistance. Both were used to calculate sensitivity, specificity, and positive and negative predictive values (PPV and NPV). Two-hour oral glucose tolerance tests (2h-OGTT) defined CFRD. Analyses were conducted separately for children and adults. Performances of HOMA-%β and HOMA-IR were calculated at inclusion, for each year of follow-up and for pooled data over the follow-up period., Results: Sensitivity, specificity, NPV and PPV were respectively: 88%, 45%, 98% and 11% for HOMA-%β and 42%, 48%, 91% and 6% for HOMA-IR in the pooled data of children; and 83%, 18%, 90% and 10% for HOMA-%β, and 39%, 80%, 92% and 18% for HOMA-IR in the pooled data of adults. Combining HOMA-%β and HOMA-IR did not improve performances., Conclusion: Within both age groups, HOMA-%β <100 provided good sensitivity and NPV. HOMA-IR >1 had low sensitivity. Calculation of the HOMA-%β could be an interesting first-line screening approach to exclude CFRD and thus avoid unnecessary OGTT in patients for whom value is ≥100. However, HOMA-%β<100 does not support the diagnosis of CFRD and should be complemented by OGTT., Competing Interests: Declaration of Competing Interest None, (Copyright © 2021. Published by Elsevier B.V.)

Published
2022
Full Text
View/download PDF

2. Toward the Standardization of Mycological Examination of Sputum Samples in Cystic Fibrosis: Results from a French Multicenter Prospective Study.

Author

Coron N, Pihet M, Fréalle E, Lemeille Y, Pinel C, Pelloux H, Gargala G, Favennec L, Accoceberry I, Durand-Joly I, Dalle F, Huet F, Fanton A, Boldron A, Loeuille GA, Domblides P, Coltey B, Pin I, Llerena C, Troussier F, Person C, Marguet C, Wizla N, Thumerelle C, Turck D, Bui S, Fayon M, Duhamel A, Prévotat A, Wallaert B, Leroy S, Bouchara JP, and Delhaes L

Subjects
Adolescent, Adult, Aged, Aged, 80 and over, Child, Female, France, Humans, Male, Middle Aged, Prospective Studies, Young Adult, Cystic Fibrosis complications, Fungi classification, Fungi isolation & purification, Lung Diseases, Fungal diagnosis, Microbiological Techniques methods, Microbiological Techniques standards, Sputum microbiology
Abstract

Fungal respiratory colonization of cystic fibrosis (CF) patients emerges as a new concern; however, the heterogeneity of mycological protocols limits investigations. We first aimed at setting up an efficient standardized protocol for mycological analysis of CF sputa that was assessed during a prospective, multicenter study: "MucoFong" program (PHRC-06/1902). Sputa from 243 CF patients from seven centers in France were collected over a 15-month period and submitted to a standardized protocol based on 6 semi-selective media. After mucolytic pretreatment, sputa were plated in parallel on cycloheximide-enriched (ACT37), erythritol-enriched (ERY37), benomyl dichloran-rose bengal (BENO37) and chromogenic (CAN37) media incubated at 37 °C and on Sabouraud-chloramphenicol (SAB27) and erythritol-enriched (ERY27) media incubated at 20-27 °C. Each plate was checked twice a week during 3 weeks. Fungi were conventionally identified; time for detection of fungal growth was noted for each species. Fungal prevalences and media performances were assessed; an optimal combination of media was determined using the Chi-squared automatic interaction detector method. At least one fungal species was isolated from 81% of sputa. Candida albicans was the most prevalent species (58.8%), followed by Aspergillus fumigatus (35.4%). Cultivation on CAN37, SAB27, ACT37 and ERY27 during 16 days provided an optimal combination, detecting C. albicans, A. fumigatus, Scedosporium apiospermum complex and Exophiala spp. with sensitivities of 96.5, 98.8, 100 and 100%. Combination of these four culture media is recommended to ensure the growth of key fungal pathogens in CF respiratory specimens. The use of such consensual protocol is of major interest for merging results from future epidemiological studies.

Published
2018
Full Text
View/download PDF

3. Sweat test practice in pediatric pulmonology after introduction of cystic fibrosis newborn screening.

Author

Grimaldi C, Brémont F, Berlioz-Baudoin M, Brouard J, Corvol H, Couderc L, Lezmi G, Pin I, Petit I, Reix P, Remus N, Schweitzer C, Thumerelle C, and Dubus JC

Subjects
Child, Child, Preschool, Cystic Fibrosis Transmembrane Conductance Regulator genetics, Female, France, Humans, Infant, Infant, Newborn, Male, Pulmonary Medicine, Retrospective Studies, Cystic Fibrosis diagnosis, Neonatal Screening methods, Sweat chemistry
Abstract

The influence of the generalization of cystic fibrosis newborn screening (CFNBS) in France on sweat test (ST) prescription is unknown. In this French retrospective, descriptive, and multicenter study, we studied the indications, number, methods, and results of STs prescribed by a pediatric pulmonologist in children who had a negative CFNBS and an ST for respiratory symptoms in 2012. We included 502 children with 523 STs, performed with four different methods. The main indication was asthma (71.3 %), then chronic cough (52.4 %), atypical lower airway infections (42.2 %), and bronchiectasis (7 %). Four children had a diagnosis of CF (0.8 %), all presenting with chronic productive cough and recurrent respiratory infections., Conclusion: Asthma is the most frequent indication of ST in our cohort. Because of the systematic CFNBS in France, some prescriptions should be avoided, particularly in case of severe or moderate asthma with no other associated symptom. Moreover, methods of STs often do not follow the guidelines and need standardization., What Is Known: • Newborn screening (NBS) has become the most frequent circumstance of the diagnosis of cystic fibrosis (CF) in France after its generalization. • The prescription of sweat test (ST) in children with respiratory symptoms who already had a negative NBS has not been studied., What Is New: • In children with a negative CF NBS referred to a university hospital for respiratory diseases, despite important variations of ST methods, only 4 children among 502 have been diagnosed as CF. • Despite recommendations, ST prescription should be avoided in children with moderate to severe asthma and no other associated symptom.

Published
2015
Full Text
View/download PDF

4. Comparing Mycobacterium massiliense and Mycobacterium abscessus lung infections in cystic fibrosis patients.

Author

Roux AL, Catherinot E, Soismier N, Heym B, Bellis G, Lemonnier L, Chiron R, Fauroux B, Le Bourgeois M, Munck A, Pin I, Sermet I, Gutierrez C, Véziris N, Jarlier V, Cambau E, Herrmann JL, Guillemot D, and Gaillard JL

Subjects
Age Distribution, Anti-Bacterial Agents therapeutic use, Chi-Square Distribution, Cohort Studies, Comorbidity, Cystic Fibrosis surgery, Female, France epidemiology, Humans, Lung Transplantation statistics & numerical data, Male, Mycobacterium Infections, Nontuberculous microbiology, Nontuberculous Mycobacteria drug effects, Nontuberculous Mycobacteria isolation & purification, Prevalence, Prognosis, Prospective Studies, Risk Assessment, Severity of Illness Index, Sex Distribution, Survival Rate, Treatment Outcome, Cystic Fibrosis epidemiology, Cystic Fibrosis microbiology, Mycobacterium Infections, Nontuberculous drug therapy, Mycobacterium Infections, Nontuberculous epidemiology, Nontuberculous Mycobacteria classification
Abstract

Background: Mycobacterium massiliense is closely related to Mycobacterium abscessus and is also a frequent cause of mycobacterial lung disease in patients with cystic fibrosis (CF). There has been no previous investigation of possible differences between M. massiliense and M. abscessus infections in the setting of CF., Methods: We studied a prospective cohort of 16 M. massiliense and 27 M. abscessus lung infection cases with CF, with a mean follow-up of 6 years., Results: M. massiliense cases were younger than M. abscessus cases (mean age: 12.8 vs 17.1 years; p=0.02) at the time of the first mycobacterial isolation and also had lower body mass index values (mean: 16.4 vs 19.3 kg/m(2), p=0.002). All M. massiliense cases, except one, had negative BMI Z-score values at the time of the first mycobacterial isolation (11/12 vs 16/23 M. abscessus cases, p=0.04). Clarithromycin-based combination therapies led to mycobacterial eradication in 100% of M. massiliense cases but only in 27% of M. abscessus cases (p=0.009)., Conclusion: Our data show a particular link between M. massiliense and malnutrition specifically in CF patients. Unlike M. abscessus, the bacteriological response of M. massiliense to combination antibiotic therapies containing clarithromycin was excellent. Distinguishing between M. massiliense and M. abscessus has major clinical implications for CF patients., (Copyright © 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.)

Published
2015
Full Text
View/download PDF

5. Central venous thrombosis and thrombophilia in cystic fibrosis: A prospective study.

Author

Munck A, Kheniche A, Alberti C, Hubert D, Martine RG, Nove-Josserand R, Pin I, Bremont F, Chiron R, Couderc L, Dalphin ML, Darviot E, Delaisi B, Dominique S, Durieu I, Fanton A, Fayon M, Gérardin M, Giniès JL, Giraut C, Grenet D, Guillot M, Huet F, Le Bourgeois M, Murris-Epin M, Ramel S, Sardet A, Sermet-Gaudelus I, Varaigne F, Wanin S, Weiss L, and Hurtaud MF

Subjects
Adolescent, Adult, Age Distribution, Child, Cohort Studies, Comorbidity, Cystic Fibrosis diagnosis, Cystic Fibrosis drug therapy, Female, Humans, Male, Prevalence, Prognosis, Prospective Studies, Severity of Illness Index, Sex Distribution, Thrombophilia blood, Ultrasonography, Doppler methods, Venous Thrombosis diagnostic imaging, Venous Thrombosis etiology, Young Adult, Catheters, Indwelling adverse effects, Cystic Fibrosis epidemiology, Thrombophilia epidemiology, Venous Thrombosis epidemiology
Abstract

Background and Aims: Catheter venous thrombosis may result in life-threatening embolic complications. Recently, a thrombophilic tendency was described in cystic fibrosis (CF), the significance of which remains unclear. The aims of this study were to (1) document the frequency of catheter venous thrombosis detected by colour-Doppler-ultrasound (Doppler-US), (2) assess genetic and acquired thrombophilia risk factors for catheter venous thrombosis and hypercoagulability status and (3) provide recommendations on laboratory screening when considering insertion of a totally implantable vascular access device (TIVAD) in CF patients., Methods: We designed a multicentre prospective study in patients selected at the time of catheter insertion. Doppler-US was scheduled at 1 and 6months after insertion and before insertion in case of a previous central line. Blood samplings were drawn at insertion and at 1 and 6months later., Results: One-hundred patients received a TIVAD and 90 completed the 6-month study. Prevalence of thrombophilia abnormalities and hypercoagulability was found in 50% of the cohorts. Conversely, catheter venous thrombosis frequency was low (6.6%)., Conclusion: Our data do not support biological screening at the time of a TIVAD insertion. We emphasise the contribution of a medical history of venous thromboembolism and prospective Doppler-US for identifying asymptomatic catheter venous thrombosis to select patients who may benefit from biological screening and possible anticoagulant therapy., (Copyright © 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.)

Published
2015
Full Text
View/download PDF

6. Toward the Standardization of Mycological Examination of Sputum Samples in Cystic Fibrosis: Results from a French Multicenter Prospective Study

Author

Coron, Noémie, Pihet, Marc, Fréalle, Emilie, Lemeille, Yolande, Pinel, Claudine, Pelloux, Hervé, Gargala, Gilles, Favennec, Loic, Accoceberry, Isabelle, Durand-Joly, Isabelle, Dalle, Frédéric, Huet, Frédéric, Fanton, Annlyse, Boldron, Amale, Loeuille, Guy-André, Domblides, Philippe, Coltey, Bérengère, Pin, Isabelle, Llerena, Catherine, Troussier, Françoise, Person, Christine, Marguet, Christophe, Wizla, Nathalie, Thumerelle, Caroline, Turck, Dominique, Bui, Stéphanie, Fayon, Michael, Duhamel, Alain, Prévotat, Anne, Wallaert, Benoit, Leroy, Sylvie, Bouchara, Jean-Philippe, and Delhaes, Laurence

Published
2017
Full Text
View/download PDF

7. Real-World Long-Term Ivacaftor for Cystic Fibrosis in France: Clinical Effectiveness and Healthcare Resource Utilization.

Author

Hubert, Dominique, Marguet, Christophe, Benichou, Jacques, DeSouza, Cynthia, Payen-Champenois, Catherine, Kinnman, Nils, Chandarana, Keval, Munck, Anne, Fajac, Isabelle, the BRIO Study Group, Ramel, Sophie, Vigneron, Philippe, Storni, Veronique, Remus, Natacha, Durieu, Laurence Bassinet Isabelle, Laurans, Muriel, Troussier, Cinthia Rames Françoise, Huet, Marie-Laure Dalphin Frédéric, Pin, Isabelle, and Payet, Boubou Camara Annabelle

Subjects
CYSTIC fibrosis transmembrane conductance regulator, CYSTIC fibrosis, FORCED expiratory volume, MEDICAL care, TREATMENT effectiveness
Abstract

Introduction: Ivacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator that has demonstrated clinical benefits in phase 3 trials. We report results from a real-world study (BRIO) to assess the effectiveness of ivacaftor in people with cystic fibrosis (pwCF) in France. Methods: BRIO was an observational study conducted at 35 centers in France. Both pwCF initiating ivacaftor treatment and those already taking ivacaftor were included and prospectively followed for 24 months. The primary objective was to evaluate the effect of ivacaftor on percent predicted forced expiratory volume in 1 s (ppFEV1); secondary objectives were evaluating the effect of ivacaftor on clinical effectiveness, healthcare resource utilization (HCRU), and safety. Results: A total of 129 pwCF were enrolled; 58.9% were aged < 18 years; 64.3% had a G551D-CFTR allele. Mean age at ivacaftor initiation was 19.1 years (range, 2–64 years); ppFEV1 increased by a least squares mean of 8.49 percentage points in the first 6 months and was sustained through 36 months of ivacaftor use. Growth metrics increased during the first 12 months post-ivacaftor and remained stable. The rate of pulmonary exacerbations (PEx) decreased during the 12 months post-ivacaftor compared with the 12 months pre-ivacaftor; estimated rate ratios (95% CI) were 0.57 (0.43–0.75) for PEx events and 0.25 (0.13–0.48) for PEx requiring hospitalization. No new safety concerns were identified; no deaths occurred. Conclusions: The results from this real-world study of ivacaftor usage in France were consistent with prior clinical trial outcomes, confirming the clinical effectiveness of ivacaftor, as well as an associated reduction in HCRU. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

8. Toward the Standardization of Mycological Examination of Sputum Samples in Cystic Fibrosis : Results from a French Multicenter Prospective Study

Author

Lafarge, Céline, Pontoire, Bruno, Cayot, Nathalie, Le Bail, Patricia, Coron, Noémie, Pihet, Marc, Fréalle, Emilie, Lemeille, Yolande, Pinel, Claudine, Pelloux, Hervé, Gargala, Gilles, Favennec, Loïc, Accoceberry, Isabelle, Durand-Joly, Isabelle, Dalle, Frédéric, Huet, Frédéric, Fanton, Annlyse, Boldron, Amale, Loeuille, Guy-André, Domblides, Philippe, Coltey, Bérengère, Pin, Isabelle, Llerena, Catherine, Troussier, Françoise, Person, Christine, Marguet, Christophe, Wizla, Nathalie, Thumerelle, Caroline, Turck, Dominique, Bui, Stéphanie, Fayon, Michael, Duhamel, Alain, Prévotat, Anne, Leroy, Sylvie, Wallaert, Benoit, Bouchara, Jean-Philippe, Delhaes, Laurence, Procédés Alimentaires et Microbiologiques [Dijon] (PAM), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université de Bourgogne (UB)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, Unité de recherche sur les Biopolymères, Interactions Assemblages (BIA), Institut National de la Recherche Agronomique (INRA), Agroécologie [Dijon], Université de Bourgogne (UB)-Institut National de la Recherche Agronomique (INRA)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, ATOMycA (CRCINA-ÉQUIPE 6), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Groupe d'Étude des Interactions Hôte-Pathogène (GEIHP), Université d'Angers (UA), Laboratoire de Parasitologie et Mycologie (Parasito - Myco - LILLE), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Université Grenoble Alpes - UFR Pharmacie (UGA UFRP), Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Pôle Biologie, Institut de Biologie et Pathologie, Centre Hospitalier Universitaire de Grenoble, Laboratoire de parasitologie-mycologie, CHU Grenoble, CHU Rouen, Normandie Université (NU), Appareil Digestif Environnement Nutrition (ADEN ), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU), Microbiologie cellulaire et moléculaire et pathogénicité (MCMP), Université Bordeaux Segalen - Bordeaux 2-Centre National de la Recherche Scientifique (CNRS), Laboratoire Interactions Muqueuses Agents Transmissibles (LIMA), Université de Bourgogne (UB), Service de pédiatrie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre de Ressources et de Compétences de la Mucoviscidose [CHU Dijon] (CRCM ), CHU Bordeaux, Ctr Rech Mucoviscidose CRCM Adulte, CHU Bordeaux [Bordeaux], CRCM Adulte [Grenoble], Institut d'oncologie/développement Albert Bonniot de Grenoble (INSERM U823), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de pédiatrie générale et maladies infectieuses, Service de Pneumologie Pédiatrique [Angers], Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Centre Robert Debré, PRES Université Nantes Angers Le Mans (UNAM), Service de pédiatrie médicale et médecine de l'adolescent [Rouen], Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Clinique de Pédiatrie, Hôpital Jeanne de Flandre [Lille]-Université de Lille, Hôpital Jeanne de Flandre [Lille], Pediatrics, CHU Bordeaux, Dept Pediat CRCM, INSERM Ctr Invest Clin CIC5, Université de Bordeaux (UB)-CHU Bordeaux [Bordeaux]-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche Cardio-thoracique de Bordeaux, U1045, Institut d'Informatique et de Mathématiques Appliquées de Grenoble (IMAG), Université Joseph Fourier - Grenoble 1 (UJF)-Institut National Polytechnique de Grenoble (INPG)-Centre National de la Recherche Scientifique (CNRS), Département de Pneumologie, Hôpital A. Calmette, Centre Hospitalier Universitaire de Nice (CHU de Nice), Service de Pneumologie et Immuno-Allergologie [CHU LIlle], Pole Cardio-vasculaire et pulmonaire [CHU Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de Parasitologie et de Mycologie [Lille], Centre de recherche Cardio-Thoracique de Bordeaux [Bordeaux] (CRCTB), Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Institut National de la Santé et de la Recherche Médicale (INSERM), French Ministry of Health and Research (PHRC N°2006/1902), the association 'Vaincre la Mucoviscidose' (Defeat Cystic Fibrosis) (MucoFong and Mucofong-ATF N8 2006/351), the Pharmaceutical Division of Pfizer France (Nu 2006/158), Université de Bourgogne (UB)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Université Bourgogne Franche-Comté [COMUE] (UBFC), FLAveur, VIsion et Comportement du consommateur (FLAVIC), Institut National de la Recherche Agronomique (INRA)-Université de Bourgogne (UB)-Etablissement National d'Enseignement Supérieur Agronomique de Dijon (ENESAD), ATIP AVENIR / ATOMycA (CRCINA - Département INCIT - Equipe 6), Centre de recherche de Cancérologie et d'Immunologie / Nantes - Angers (CRCINA), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Groupe d'Etude des Interactions Hôte-Parasite (GEIHP), Université Grenoble Alpes (UGA), Service de Pédiatrie, Centre de Ressources et de Compétences de la Mucoviscidose [Dijon], Service de Pneumologie et Immuno-Allergologie, Centre hospitalier universitaire de Nantes (CHU Nantes)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Nantes (UN)-Université d'Angers (UA)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Nantes (UN)-Université d'Angers (UA), Service de Parasitologie-Mycologie [CHRU LIlle], Institut de Microbiologie [CHRU Lille], Pôle de Biologie Pathologie Génétique [CHU Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Pôle de Biologie Pathologie Génétique [CHU Lille], Centre Hospitalier Universitaire [Grenoble] (CHU), université de Bourgogne, PAM, Hôpital Charles Nicolle [Rouen], Université de Bordeaux (UB), CH Dunkerque, Centre de Recherche en Chimie Moléculaire (CRCM), Université Sciences et Technologies - Bordeaux 1 (UB)-Centre National de la Recherche Scientifique (CNRS), Groupe de Recherche sur les Antimicrobiens et les Micro-Organismes (GRAM 1.0), CHU Lille, CIC Bordeaux, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'Etudes et de Recherche en Informatique Médicale [Lille] (CERIM), Hôpital Pasteur [Nice] (CHU), Centre Hospitalier Universitaire de Nice (CHU Nice), Procédés Alimentaires et Microbiologiques [Dijon] ( PAM ), Université de Bourgogne ( UB ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Université Bourgogne Franche-Comté ( UBFC ), Unité de recherche sur les Biopolymères, Interactions Assemblages ( BIA ), Institut National de la Recherche Agronomique ( INRA ), FLAveur, VIsion et Comportement du consommateur ( FLAVIC ), Etablissement National d'Enseignement Supérieur Agronomique de Dijon ( ENESAD ) -Institut National de la Recherche Agronomique ( INRA ) -Université de Bourgogne ( UB ), ATIP AVENIR / ATOMycA ( CRCINA - Département INCIT - Equipe 6 ), Centre de recherche de Cancérologie et d'Immunologie / Nantes - Angers ( CRCINA ), Université d'Angers ( UA ) -Université de Nantes ( UN ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Institut de Recherche en Santé de l'Université de Nantes ( IRS-UN ) -Centre hospitalier universitaire de Nantes ( CHU Nantes ) -Université d'Angers ( UA ) -Université de Nantes ( UN ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Institut de Recherche en Santé de l'Université de Nantes ( IRS-UN ) -Centre hospitalier universitaire de Nantes ( CHU Nantes ), Groupe d'Etude des Interactions Hôte-Parasite ( GEIHP ), Université d'Angers ( UA ), Laboratoire de Parasitologie et Mycologie ( Parasito - Myco - LILLE ), Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ), Université Grenoble Alpes - UFR Pharmacie ( UGA UFRP ), Université Grenoble Alpes ( UGA ), Appareil Digestif Environnement Nutrition ( ADEN ), Université de Rouen Normandie ( UNIROUEN ), Normandie Université ( NU ) -Normandie Université ( NU ), Microbiologie cellulaire et moléculaire et pathogénicité ( MCMP ), Université Bordeaux Segalen - Bordeaux 2-Centre National de la Recherche Scientifique ( CNRS ), Laboratoire Interactions Muqueuses Agents Transmissibles ( LIMA ), Université de Bourgogne ( UB ), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Institut d'oncologie/développement Albert Bonniot de Grenoble ( INSERM U823 ), Université Joseph Fourier - Grenoble 1 ( UJF ) -CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre Hospitalier Universitaire d'Angers-Centre Robert Debré, Centre Hospitalier Universitaire d'Angers ( CHU Angers ), PRES Université Nantes Angers Le Mans ( UNAM ), CHU Rouen-Université de Rouen Normandie ( UNIROUEN ), Université de Bordeaux ( UB ) -CHU Bordeaux [Bordeaux]-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre Hospitalier Universitaire de Bordeaux, Institut d'Informatique et de Mathématiques Appliquées de Grenoble ( IMAG ), Université Joseph Fourier - Grenoble 1 ( UJF ) -Institut National Polytechnique de Grenoble ( INPG ) -Centre National de la Recherche Scientifique ( CNRS ), Centre Hospitalier Universitaire de Nice ( CHU de Nice ), Centre de recherche Cardio-Thoracique de Bordeaux [Bordeaux] ( CRCTB ), and Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Institut National de la Santé et de la Recherche Médicale ( INSERM )

Subjects
Adult, Male, Microbiological Techniques, 0301 basic medicine, medicine.medical_specialty, Filamentous fungi, Adolescent, Veterinary (miscellaneous), Lung mycobiota, 030106 microbiology, Biology, Applied Microbiology and Biotechnology, Microbiology, Cystic fibrosis, Aspergillus fumigatus, Molds, Young Adult, 03 medical and health sciences, Medical microbiology, Exophiala, Mycological examination, medicine, Humans, Prospective Studies, Child, Candida albicans, [ SDV.MP.MYC ] Life Sciences [q-bio]/Microbiology and Parasitology/Mycology, [SDV.MP.MYC]Life Sciences [q-bio]/Microbiology and Parasitology/Mycology, Aged, Aged, 80 and over, Aspergillus, Lung Diseases, Fungal, Fungi, Sputum, Scedosporium apiospermum, Middle Aged, biology.organism_classification, [SDV.MP.MYC] Life Sciences [q-bio]/Microbiology and Parasitology/Mycology, Corpus albicans, 030104 developmental biology, Female, France, medicine.symptom, Agronomy and Crop Science
Abstract

IF 1.710; International audience; Fungal respiratory colonization of cystic fibrosis (CF) patients emerges as a new concern; however, the heterogeneity of mycological protocols limits investigations. We first aimed at setting up an efficient standardized protocol for mycological analysis of CF sputa that was assessed during a prospective, multicenter study: “MucoFong” program (PHRC-06/1902). Sputa from 243 CF patients from seven centers in France were collected over a 15-month period and submitted to a standardized protocol based on 6 semi-selective media. After mucolytic pretreatment, sputa were plated in parallel on cycloheximide-enriched (ACT37), erythritol-enriched (ERY37), benomyl dichloran–rose bengal (BENO37) and chromogenic (CAN37) media incubated at 37 °C and on Sabouraud–chloramphenicol (SAB27) and erythritol-enriched (ERY27) media incubated at 20–27 °C. Each plate was checked twice a week during 3 weeks. Fungi were conventionally identified; time for detection of fungal growth was noted for each species. Fungal prevalences and media performances were assessed; an optimal combination of media was determined using the Chi-squared automatic interaction detector method. At least one fungal species was isolated from 81% of sputa. Candida albicans was the most prevalent species (58.8%), followed by Aspergillus fumigatus (35.4%). Cultivation on CAN37, SAB27, ACT37 and ERY27 during 16 days provided an optimal combination, detecting C. albicans, A. fumigatus, Scedosporium apiospermum complex and Exophiala spp. with sensitivities of 96.5, 98.8, 100 and 100%. Combination of these four culture media is recommended to ensure the growth of key fungal pathogens in CF respiratory specimens. The use of such consensual protocol is of major interest for merging results from future epidemiological studies.

Published
2018

9. Respiratory mycobiome and suggestion of inter-kingdom network during acute pulmonary exacerbation in cystic fibrosis.

Author

Soret, Perrine, Vandenborght, Louise-Eva, Francis, Florence, Coron, Noémie, Enaud, Raphael, Avalos, Marta, Schaeverbeke, Thierry, Berger, Patrick, Fayon, Michael, Thiebaut, Rodolphe, Delhaes, Laurence, The Mucofong Investigation Group, Chabe, Magali, Audebert, Christophe, Durand-Joly, Isabelle, Boldron, Amale, Pin, Isabelle, Cognet, Odile, Pelloux, Herve, and Prevotat, Anne

Subjects
LUNG infections, MYCOBIOME, DISEASE exacerbation, CYSTIC fibrosis, RIBOSOMAL RNA
Abstract

Lung infections play a critical role in cystic fibrosis (CF) pathogenesis. CF respiratory tract is now considered to be a polymicrobial niche and advances in high-throughput sequencing allowed to analyze its microbiota and mycobiota. However, no NGS studies until now have characterized both communities during CF pulmonary exacerbation (CFPE). Thirty-three sputa isolated from patients with and without CFPE were used for metagenomic high-throughput sequencing targeting 16S and ITS2 regions of bacterial and fungal rRNA. We built inter-kingdom network and adapted Phy-Lasso method to highlight correlations in compositional data. The decline in respiratory function was associated with a decrease in bacterial diversity. The inter-kingdom network revealed three main clusters organized around Aspergillus, Candida, and Scedosporium genera. Using Phy-Lasso method, we identified Aspergillus and Malassezia as relevantly associated with CFPE, and Scedosporium plus Pseudomonas with a decline in lung function. We corroborated in vitro the cross-domain interactions between Aspergillus and Streptococcus predicted by the correlation network. For the first time, we included documented mycobiome data into a version of the ecological Climax/Attack model that opens new lines of thoughts about the physiopathology of CF lung disease and future perspectives to improve its therapeutic management. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results